Scaling up a bioprocess from lab to production fundamentally alters physical properties like oxygen transfer (KLA). This change in physics, not necessarily a procedural mistake, is often the root cause of failure at scale, leading to different cell growth and product quality.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

The misconception that automation equals simplicity causes teams to underestimate the need for experts in assay development, biology, and data analysis. This leads to poorly designed experiments and unreliable data when teams believe complex systems require just 'pushing a button.'

Scaling from a T-flask to a bioreactor isn't just increasing volume; it's a fundamental shift in the biological context. Changes in cell density, mass transfer, and mechanical stress rewire cell signaling. Therefore, understanding and respecting the cell's biology must be the primary design input for successful scale-up.

The standard practice is to optimize for productivity (titer) first, then correct for quality (glycosylation) later. This is reactive and inefficient. Successful teams integrate glycan analysis into their very first screening experiments, making informed, real-time trade-offs between productivity and quality attributes.

The primary obstacle to creating sophisticated AI models of cells isn't the AI itself, but the data. Existing datasets often perturb only one cellular variable at a time, failing to capture the complex interactions that arise from simultaneous changes. New platforms are needed to generate this multi-dimensional data.

A common error is screening strains or media in a simple batch mode when the final process will be fed-batch. This mismatch leads to incorrect candidate ranking and selection, forcing teams to restart the development process once the error becomes apparent during scale-up.

Instead of one massive experiment, split numerous factors into smaller, biologically-themed groups. Running these focused experiments in parallel is superior to both one-factor-at-a-time and large DOE approaches, as it maintains the breadth of a large screen while providing the high-quality signal of a small one.

When running multiple independent but parallel experiments, include well-characterized compounds in every group. These "anchor compounds" serve as internal calibration references, creating a baseline that allows for robust and reliable comparison of results across the otherwise separate experimental sets.